501 related articles for article (PubMed ID: 15850677)
1. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives.
Mandel S; Weinreb O; Amit T; Youdim MB
Brain Res Brain Res Rev; 2005 Apr; 48(2):379-87. PubMed ID: 15850677
[TBL] [Abstract][Full Text] [Related]
2. Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition.
Youdim MB; Bar Am O; Yogev-Falach M; Weinreb O; Maruyama W; Naoi M; Amit T
J Neurosci Res; 2005 Jan 1-15; 79(1-2):172-9. PubMed ID: 15573406
[TBL] [Abstract][Full Text] [Related]
3. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
[TBL] [Abstract][Full Text] [Related]
4. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.
Weinreb O; Amit T; Bar-Am O; Youdim MB
Prog Neurobiol; 2010 Nov; 92(3):330-44. PubMed ID: 20600573
[TBL] [Abstract][Full Text] [Related]
5. Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline.
Youdim MB; Maruyama W; Naoi M
Drugs Today (Barc); 2005 Jun; 41(6):369-91. PubMed ID: 16110345
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
7. Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: interaction of Bcl-2 family members with PKC pathway.
Weinreb O; Amit T; Bar-Am O; Chillag-Talmor O; Youdim MB
Ann N Y Acad Sci; 2005 Aug; 1053():348-55. PubMed ID: 16179541
[TBL] [Abstract][Full Text] [Related]
8. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
Guay DR
Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
[TBL] [Abstract][Full Text] [Related]
9. Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo.
Bar-Am O; Yogev-Falach M; Amit T; Sagi Y; Youdim MB
J Neurochem; 2004 Jun; 89(5):1119-25. PubMed ID: 15147504
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease.
Chen JJ; Swope DM
J Clin Pharmacol; 2005 Aug; 45(8):878-94. PubMed ID: 16027398
[TBL] [Abstract][Full Text] [Related]
11. Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate].
Youdim MB; Weinstock M
Cell Mol Neurobiol; 2001 Dec; 21(6):555-73. PubMed ID: 12043833
[TBL] [Abstract][Full Text] [Related]
12. The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline.
Bar-Am O; Weinreb O; Amit T; Youdim MB
J Neurochem; 2010 Mar; 112(5):1131-7. PubMed ID: 20002521
[TBL] [Abstract][Full Text] [Related]
13. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
Fernandez HH; Chen JJ
Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750
[TBL] [Abstract][Full Text] [Related]
14. Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation.
Bar-Am O; Amit T; Weinreb O; Youdim MB; Mandel S
J Alzheimers Dis; 2010; 21(2):361-71. PubMed ID: 20555137
[TBL] [Abstract][Full Text] [Related]
15. Rasagiline: an anti-Parkinson drug with neuroprotective activity.
Youdim MB
Expert Rev Neurother; 2003 Nov; 3(6):737-49. PubMed ID: 19810877
[TBL] [Abstract][Full Text] [Related]
16. Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.
Naoi M; Maruyama W
Expert Rev Neurother; 2009 Aug; 9(8):1233-50. PubMed ID: 19673610
[TBL] [Abstract][Full Text] [Related]
17. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease.
Weinreb O; Amit T; Riederer P; Youdim MB; Mandel SA
Int Rev Neurobiol; 2011; 100():127-49. PubMed ID: 21971006
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotection by rasagiline: a new therapeutic approach to Parkinson's disease?
Blandini F
CNS Drug Rev; 2005; 11(2):183-94. PubMed ID: 16007239
[TBL] [Abstract][Full Text] [Related]
20. The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30.
Youdim MB
Curr Alzheimer Res; 2006 Dec; 3(5):541-50. PubMed ID: 17168653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
